| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2011: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2010: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2009: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Research Abstract |
(Basic) We explored the mRNA expression of angiogenesis-related or cell proliferation-related genes (total 37 genes) in 26 hepatocarcinoma tissues. Only HIF1α expression was correlated with pathological differentiation, tumor vascularity, and macroscopic vascular invasion. (Clinical)We explored the predictive marker for the treatment efficacy of sorafenib in 54 hepatocellular carcinoma patients and revealed that modified RECIST findings and AFP level were useful for the prediction of the efficacy of the sorafenib treatment.
|
